Business
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today issued the following letter to shareholders from its Chief Executive Officer, Eyal Shamir.
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Company experiencing strong demand in the U.S. following FDA marketing authorization of ProSense® as the only on-label minimally invasive solution for the local treatment of low-risk breast cancer, addressing a market opportunity of approximately 200,000 patients","length":268,"tagName":"p","attribs":{}},{"type":"text","content":"Record European sales, driven by positive effects of U.S. clearance and continued growing adoption of ProSense® cryoablation for breast cancer in key markets","length":162,"tagName":"p","attribs":{}},{"type":"text","content":"Record number of peer-reviewed publications and presentations at global conferences demonstrates growing clinical evidence for cryoablation of breast, musculoskeletal, and kidney cancers with ProSense®","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"CAESAREA, Israel, Jan. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today issued the following letter to shareholders from its Chief Executive Officer, Eyal Shamir.","length":393,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2XUcwzAVdZCf5Oz2LQaIEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc","width":400,"height":200}}},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"Dear shareholders,","length":18,"tagName":"p"},{"type":"text","content":"2025 was a pivotal year for IceCure – we were granted the U.S. Food and Drug Administration's ("FDA") marketing authorization for ProSense® cryoablation for the local treatment of low-risk breast cancer with endocrine therapy in women aged 70 and above, including those who are not candidates for breast cancer surgery. This achievement has strengthened our belief that ProSense® can expand patient choice, enhance care, an...